Ibalizumab (TMB-355) 是一种人源化 IgG4 单克隆抗体，通过与 CD4 受体结合来阻止 HIV 细胞进入。Ibalizumab 具有用于 HIV-1 感染研究的潜力。
| 产品描述 | Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research[1]. [1]. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785. |
m.cnreagent.com